araag2/HINT huggingface dataset:
Clinical trial NCT01494012 (phase 1, status: terminated)
Conditions: recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, malignant tumor of peritoneum, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor
ICD codes: H18.523, H18.521, H18.522, H18.529, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2, C48.2, C48.1, C78.6, C48.8, H18.523, H18.521, H18.522, H18.529
Drugs: fludeoxyglucose f 18
SMILES: [H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have persistent, metastatic, or recurrent platinum resistant or
             refractory ovarian or primary peritoneal cancer.

          -  No restriction on previous treatment regimens, but patients must be at least 2 weeks
             out from last chemotherapy or investigational agent.

          -  Patients must be >= 18.

          -  Patients must have a life expectancy of at least 6 months.

          -  Patients must have KPS >= 60.

          -  Patients must have acceptable organ and marrow function as defined below (within 2
             weeks prior to radiotherapy):

               -  leukocytes >=3,000/uL

               -  absolute neutrophil count >=1,500uL

               -  platelets >=100,000/uL

               -  total bilirubin within 1.5X normal institutional limits

               -  AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal

               -  creatinine within normal institutional limits OR

               -  creatinine clearance >=60 mL/min/1.73 m^2 for patients with creatinine levels
                  above institutional normal

          -  Patients must be willing to undergo a pre- and post-treatment FDG-PET/CT.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients should not have received radiation overlapping with the proposed treatment
             field.

          -  Patients cannot be receiving chemotherapy or other investigation agents from two weeks
             prior to radiation through undergoing their post-therapy FDG-PET/CT

          -  Patients cannot be pregnant or nursing.

          -  Patients cannot have disease >= 8cm or greater than 3 regions of disease.

          -  Patients cannot have concurrent malignancy other than non-melanoma skin cancer,
             non-invasive bladder cancer, or carcinoma in situ of the cervix.
Clinical trial NCT01159847 (phase 1/phase 2, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: sitagliptin, insulin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diabetes diagnosed according to the report of WHO in 1999.

          2. Age at onset between 25~70 years.

          3. Disease duration of less than 3 year.

          4. No ketoacidosis within the first 6 months after diagnosis of diabetes.

          5. GADA positive twice within one month.

          6. Fasting C-peptide (FCP) level of 0.2 nmol/L or more.

        Exclusion Criteria:

          1. Insulin requirements more than 0.8 units/kg/day.

          2. Evidence of chronic infection or acute infection affected blood glucose control within
             4 weeks prior to visit 1.

          3. History of any malignancy.

          4. Pregnancy, breastfeeding or planned pregnancy within two years.

          5. Secondary diabetes.

          6. Congestive heart failure requiring pharmacologic treatment.

          7. Renal disease or renal dysfunction or diabetic nephropathy suggested by serum
             creatinine levels≥1.5 mg/dL (132μmol/L) for males and ≥1.4mg/dL (123μmol/L) for
             females or abnormal creatinine clearance at Visit 1.

          8. Concurrent medical condition that may interfere with the interpretation of efficacy
             and safety data during the study.
Clinical trial NCT01360827 (phase 1, status: terminated)
Conditions: squamous cell carcinoma of the head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: emd 1201081 + 5-fu + cisplatin + cetuximab, emd 1201081 + 5-fu + cisplatin + cetuximab
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    study terminated due to potential safety concerns in combination with platinum-based therapies
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the
             head and neck (SCCHN).

          -  Recurrent and/or metastatic SCCHN, not suitable for local therapy.

          -  At least 1 measurable lesion either by computerized tomography (CT) scan or magnetic
             resonance imaging (MRI) (according to RECIST 1.0).

          -  Karnofsky performance status (KPS) of ≥ 70 / Eastern Cooperative Oncology Group
             performance status (ECOG PS) of 0 or 1 at trial entry.

        Exclusion Criteria:

          -  Prior systemic chemotherapy, except if given as part of a multimodal treatment for
             locally advanced disease which was completed more than 2 months prior to trial entry.

          -  Nasopharyngeal carcinoma.

          -  Medical history of diagnosed interstitial lung disease.

          -  Known hypersensitivity against any of the components of the trial treatment.

          -  Previous treatment with experimental or non-approved epidermal growth factor receptor
             (EGFR) targeting therapy or experimental or nonapproved EGFR signal transduction
             inhibitors (prior treatment with cetuximab is allowed).

          -  Relevant cardiovascular co-morbidities.

          -  Concomitant chronic systemic immune therapy, or hormonal therapy as cancer therapy,
             steroid use ≥ 10 mg prednisone equivalent.

          -  Known human immunodeficiency virus (HIV) positivity, active hepatitis C, or active
             hepatitis B.
Clinical trial NCT00657280 (early phase 1, status: completed)
Conditions: heart failure, congestive
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: sitagliptin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-III congestive
             heart failure

          2. Treatment with a stable comprehensive heart failure regimen for at least 3 months
             (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless
             intolerant)

          3. Age > 18 yrs

        Exclusion Criteria:

          1. Cardiomyopathy primarily due to one of the following:

               1. Ischemic heart disease

               2. Primary valvular lesion

               3. Hypertrophic cardiomyopathy

          2. Cardiac resynchronization within the last 3 months

          3. Calculated creatinine clearance <30 ml/min or end-stage renal disease on dialysis.
             Creatinine clearance will be determined by the Cockcroft-Gault formula.

          4. Diagnosis of diabetes mellitus by:

               1. Diabetes previously diagnosed per patient history

               2. 2 or more fasting glucose values > 125 mg/dl

          5. History of heart transplantation

          6. Pregnancy or active breast feeding

          7. Hospitalization for decompensated heart failure within 30 days prior to enrollment.
Clinical trial NCT01619332 (phase 1/phase 2, status: completed)
Conditions: type ii diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: placebo, sitagliptin, lez763
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion criteria:

          -  All subjects: (suggest this will reduce duplication)

          -  Male or female aged 18-65 yr,

          -  Subjects must weigh at least 50 kg to participate in the study. Body mass index (BMI)
             must be within the range of 18-37 kg/m2 (inclusive

          -  Only postmenopausal females or female subjects who report surgical sterilization
             (women without child bearing potential) will be allowed in this study.

          -  Subjects with stable conventional sleep-wake cycle

        Normal Healthy Volunteers

          -  Healthy male or female subjects,

          -  must be in good health (as determined by past medical history, physical examination,
             vital signs, electrocardiogram, and laboratory tests at Screening).

        Type II Diabetic Patients

          -  Type 2 diabetes diagnosed by American Diabetes Association criteria for at least 3
             months prior to screening.

          -  Patients either drug naïve or on stable dose of metformin (stable dose for at least 4
             weeks prior to Screening). The metformin dose should remain constant during the course
             of the study.

          -  HbA1c 6.5 to 9.5 % inclusive at screening

        Exclusion criteria:

        All subjects:

          -  Smokers (use of tobacco products in the previous 3 months).

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or
             longer if required by local regulation.

          -  Significant illness within two weeks prior to dosing.

          -  Have (or have history of) drug or alcohol abuse within the 12 months prior to dosing
             or evidence of such abuse as indicated by the laboratory assays conducted during the
             screening or baseline evaluations

        Normal Healthy Volunteers

        • History of diabetes, or adrenal disorders.

        Type II Diabetic Patients

          -  Type 1 diabetes mellitus; positive anti-GAD antibodies; acquired or secondary forms of
             diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis
             related diabetes

          -  Evidence of clinically significant diabetic complications (such nephropathy,
             retinopathy, neuropathy) Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT01132625 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: auy922
SMILES: CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with advanced malignant solid tumors

          -  ECOG Performance Status of ≤ 2

          -  Patients must have the following laboratory values:

          -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Hemoglobin (Hgb) ≥ 8.5 g/dl, Platelets
             (plt) ≥ 100 x 109/L

          -  Potassium, Calcium, Magnesium, Phosphorus within normal limits or correctable with
             supplements

          -  AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN)

          -  Serum bilirubin ≤ 1.5 x ULN, Serum albumin > 2.5g/dl, Serum creatinine≤ 1.5 x ULN or
             24-hour clearance ≥ 50 ml/min

          -  Able to sign informed consent and to comply with the protocol

        Exclusion Criteria:

          -  Patients with brain metastasis.

          -  Prior treatment with any HSP90 or HDAC inhibitor compound.

          -  Treatment with therapeutic doses of coumarin anticoagulants.

          -  Pregnant and lactating women.

          -  Severe and/or uncontrolled acute or chronic liver disease

          -  Severe and/or uncontrolled acute or chronic renal disease

          -  Chronically significant heart disease

          -  History (or family history) of long QT syndrome. QTc ≥ 450 msec on screening ECG,
             ischemic heart disease, heart fail, ECG abnormalities, atrial fibrillation, atrial
             flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de
             Pointes.

          -  Patients who are currently receiving treatment with any medication which has a
             relative risk or prolonging the QTcF interval or inducing Torsades de Pointes

          -  Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g
             Gilbert's syndrome).

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00063583 (phase 1/phase 2, status: completed)
Conditions: diabetes mellitus, diabetic nephropathy
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, E10.21, E11.21, E13.21, E08.21, E09.21
Drugs: pirfenidone
SMILES: CC1=CN(C(=O)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion

          -  Type 1 or type 2 diabetes

          -  Males and females greater than or equal to 18 years.

          -  Abnormal kidney function determined by glomerular filtration rate

          -  History of proteinuria

          -  Blood pressure controlled to <140/90 on anti-hypertensive medication

        Exclusion

          -  Cancer, liver disease, hepatitis, HIV+

          -  History of heart attack, unstable angina, stroke or peptic ulcer in the past 6 months

          -  Pregnant or planning to become pregnant during the study period

          -  Other known kidney disease besides diabetic nephropathy

          -  Expect to begin dialysis or receive a kidney transplant within 1 year of study
             enrollment
Clinical trial NCT00456833 (phase 1, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: rad001, erlotinib
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion criteria:

          -  Age over 18 years

          -  Advanced Non Small Cell Lung Cancer which is not responding to chemotherapy treatment
             including either cisplatin or carboplatin

          -  Only 1-2 previous chemotherapy regimens for advanced disease

          -  More than 2 weeks from previous surgery, radiation or chemotherapy

          -  Ability to perform normal daily functions

        Exclusion criteria:

          -  Chronic steroid treatment

          -  Prior treatment with EGFR inhibitors

          -  Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers,
             eye conditions or other severe medical conditions

          -  Other cancers within the past 2 years

          -  Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria
             may apply
Clinical trial NCT02043756 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: mitoxantrone hydrochloride liposome, mitoxantrone
SMILES: OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients must compliance with the requirements and restrictions listed in the consent
             form

          -  Patients with Pathology and / or cytologically proven malignant solid tumor

          -  Patients must be 18-70 years old ,both male and female

          -  Failure of standard chemotherapy

          -  Patients have no better choice and may be benefit from the use of anthracyclines

          -  Patients must have Eastern Cooperative Oncology Group (ECOG)Performance Status of 0-2

          -  Objective tumor from the last chemotherapy, biological therapy or other experimental
             interval treatment least 4 weeks

          -  Expected survival time ≥ 3 months

          -  Patients agreed to take effective contraceptive measures during the trial

          -  Blood routine, liver and kidney function, cardiac function examination in accordance
             with the following requirements.

        Exclusion criteria:

          -  Pregnancy and breast-feeding women

          -  Multiple sclerosis

          -  Patients that have histories of ischemic heart disease and heart congestive,arrhythmia
             that need to be a treatment and significant valvular disease

          -  Patients with heart disease induced by anthracycline

          -  Patients requiring other antineoplastic treatment

          -  Patients with temperature above 38 degrees or active infection that may effects in
             clinical tests

          -  Patients are allergic to anthracycline and liposomal drugs

          -  Patients are allergic to eggs,egg products,soybean and soybean products

          -  Patients with uncontrolled primary or metastatic brain tumors
Clinical trial NCT01187836 (phase 1/phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: trv120027, placebo
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of congestive heart failure made at least 3 months prior to screening

          -  NYHA Class III or IV heart failure, ejection fraction </= 35% and , and in the opinion
             of the investigator, right-heart catheterization is clinically indicated.

          -  Baseline mean PCWP >/= 20 mmHg

          -  Systolic blood pressure at screening must be >/= 100 mmHg. Heart rate at screening
             must be </= 90 bpm.

        Exclusion Criteria:

          -  Any significant disease or condition that would interfere with the interpretation of
             safety or efficacy in this study as determined by the Investigator based on medical
             history, physical examination or laboratory tests.

          -  Significant valve disease

          -  Current signs or symptoms of acute myocardial ischemia or acute coronary syndrome
             (ACS) or coronary revascularization in the past 3 months.

          -  Sustained or uncontrolled ventricular arrhythmia. Inclusion of patients with atrial
             fibrillation with a heart rate ≤ 90 bpm is permitted.
Clinical trial NCT01062152 (phase 1, status: completed)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: ezatiostat hydrochloride, lenalidomide (revlimid®)
SMILES: CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C1=CC=CC=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic diagnosis of primary or de novo MDS using WHO classification

          -  Non-del(5q) low or Intermediate-1risk MDS

          -  ECOG performance status of 0-1

          -  Documented significant cytopenia for at least 2 months

          -  Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior
             to study entry

          -  All study participants must be registered into the mandatory RevAssist® program and be
             willing and able to comply with the requirements of RevAssist®

          -  Females of childbearing potential should have two negative serum pregnancy tests with
             a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14
             days, and the second test within 24 hours of prescribing lenalidomide (prescriptions
             must be filled within seven days)

        Exclusion Criteria:

          -  Known hypersensitivity to Telintra™ (intravenous or oral)

          -  Known prior therapy with or hypersensitivity to thalidomide or lenalidomide

          -  Prior allogenic bone marrow transplant for MDS

          -  History or prior malignancy

               -  Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin
                  cancer, or other cancers (e.g. breast, prostate) for which patient has been
                  disease-free for at least 3 years.

          -  MDS evolving from:

               -  A pre-existing myeloproliferative disorder

               -  An autoimmune disease

               -  Secondary to prior treatment with radiation or chemotherapy

          -  History of MDS IPSS score>1.0

          -  Pregnant or lactating women

          -  Leptomeningeal or leukemic meningitis

          -  Prior treatment with DNA methyltransferase inhibitors (DMTI) [e.g., azacitadine,
             decitabine, etc.]
Clinical trial NCT00650572 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: arry-380, her2 inhibitor; oral
SMILES: CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1
Eligibility criteria:

        Key Inclusion Criteria (Part 1 and Part 2):

          -  Histological or cytological evidence of HER2+ cancer (Part 1) or HER2+ metastatic
             breast cancer (Part 2).

          -  Patients should have received at least one previous therapeutic regimen and either no
             longer are candidates for standard therapy, have no standard therapy available, or
             choose not to pursue standard therapy (patients with HER2+ breast cancer and with
             clinical indication for trastuzumab or lapatinib should have received prior therapy
             with trastuzumab and lapatinib, if available).

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) between 0 and 2.

          -  Additional criteria exist.

        Key Exclusion Criteria (Part 1 and Part 2):

          -  Uncontrolled or symptomatic brain metastases (patients may be considered adequately
             controlled if on a stable steroid dose for at least 30 days).

          -  Treatment with an investigational medicinal product or device within 30 days prior to
             first dose of study drug.

          -  Radiotherapy within 28 days prior to first dose of study drug (not including
             palliative radiotherapy at focal sites).

          -  Chemotherapy within 21 days prior to first dose of study drug.

          -  Major surgery within 30 days prior to first dose of study drug.

          -  Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or
             active hepatitis C.

          -  Additional criteria exist.
Clinical trial NCT01775189 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: alo-02 weight-matched placebo, crushed alo-02 30 mg/3.6 mg, oxycodone weight-matched placebo, crushed oxycodone ir 30 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy subjects

          -  Non-dependent, recreational opioid users. (Must use opioid for non-therapeutic
             purposes on at least 10 occassions within the last year and at least once in the 8
             weeks before Visit 1 (Screening Visit).

          -  Must have experience with intranasal opioid administration (snorted opioid drugs on at
             least 3 occassions within the last year before Visit 1 (Screening Visit).

        Exclusion Criteria:

          -  Diagnosis of substance and/or alcohol dependence

          -  Subject has participated in, is currently participating in, or seeking treatment for
             substance and/or alcohol related disorder.